Analyst Research Report Snapshot

Title:

Spark Capital: Corporation Bank 2QFY14 Result Review - Capital constraint compounds asset quality concerns: Maintain SELL

Price:

$58.00

Provider:

Spark Capital Advisors(India) Private Limited

Date:

13 Nov 2013

Pages:

7

Type:

AcrobatPDF

Companies referenced:

CRBK.NS

Available for Immediate Download
Summary:

Corporation Bank 2QFY14 Result Review - Capital constraint compounds asset quality concerns: Maintain SELL Corporation bank’s (CRPBK) 2QFY14 performance was marked by continuing asset quality stresses, with incremental slippages of 3.9% (annualised) translating into a 41% qoq rise in GNPAs. The overall stock of restructuring currently stands at 5.5% of the book; the restructured book has risen 2x since 2QFY12 while slippages on the 2QFY12 book are only 11% - an outlier compared to 30-40% slippage numbers reported by larger peers. Additionally, risky sector exposures have risen to 29% of the book against 25% in 1QFY13 while exposure to power is up 21% yoy to 10% of the book. PSL lending currently stands at 36% of ANBC and notwithstanding a 34% yoy rise in agri loans, agri continues to amount to only 9.1% of ANBC much below the mandated 18%; we expect both NIMs and asset quality to remain under pressure as these loans take-off. Opex was up 32% yoy, while pension liabilities are likely to be challenging in a wage revision year as CRPBK’s skewed rate of return on plan assets (9% against 8% for most PSU banks) could mean a two-fold impact on costs, a key risk in our view. CRPBK’s low T1 capital (at 7.1%) would necessitate repeated infusions of capital as the transition to BASEL 3 begins, we estimate a capital requirement of ~Rs.15bn every year over FY14-18 to support a 20% growth in RWAs (refer our note on BASEL 3 dated Aug 28, 2013). For FY14, the bank has only been allocated Rs. 4.5bn – capital infusion below book value at CMP would result in a 7% hit to FY14 ABV. We also note a sharp spike in loans to iron and steel (up 42% yoy), gems & jewellery (up 38% yoy) and textiles (up 28% yoy), adding to concerns of a 39% yoy growth in SME loans. With multiple headwinds continuing in the form of asset quality pressures, margins, capital, costs and profitability we maintain our SELL rating with a target price of Rs. 215, 0.7x our stress case FY14E ABV.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.